Literature DB >> 28566254

Challenges of vaccine presentation and delivery: How can we design vaccines to have optimal programmatic impact?

Birgitte K Giersing1, Anna-Lea Kahn2, Courtney Jarrahian3, Mercy Mvundura4, Carmen Rodriguez5, Hiromasa Okayasu6, Darin Zehrung7.   

Abstract

Immunization program delivery strategies that enable high vaccine coverage, particularly in inaccessible and remote areas, are critical to achieving optimal vaccine impact. In addition to demonstration of safety and efficacy, there are many factors that influence whether a newly licensed vaccine will be introduced into a country's national immunization program, particularly in resource-constrained environments. This paper describes three case studies of novel approaches that represent the potential for improved programmatic impact by increasing vaccine accessibility in different ways. However, the pathway to regulatory approval, policy recommendation, and program introduction in low- and middle-income countries is complex, requiring engagement with multiple, diverse stakeholders. Consideration of aspects that affect uptake in low- and middle-income countries, during the product development stage, will help better position new or second-generation vaccine products for successful implementation to achieve public health impact.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Delivery technologies; Low- and middle-income countries; Prequalification; Product development; Programmatic suitability; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 28566254     DOI: 10.1016/j.vaccine.2017.04.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Global vaccine action plan lessons learned I: Recommendations for the next decade.

Authors:  Noni MacDonald; Ezzeddine Mohsni; Yagob Al-Mazrou; Jon Kim Andrus; Narendra Arora; Susan Elden; Marie-Yvette Madrid; Rebecca Martin; Amani Mahmoud Mustafa; Helen Rees; David Salisbury; Qinjian Zhao; Ian Jones; Christoph A Steffen; Joachim Hombach; Katherine L O'Brien; Alejandro Cravioto
Journal:  Vaccine       Date:  2020-05-05       Impact factor: 3.641

Review 2.  A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination.

Authors:  Mark R Prausnitz; James L Goodson; Paul A Rota; Walter A Orenstein
Journal:  Curr Opin Virol       Date:  2020-07-01       Impact factor: 7.090

3.  Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations.

Authors:  Mercy Mvundura; Collrane Frivold; Anna Janik Osborne; Priyanka Soni; Joanie Robertson; Sandeep Kumar; Jacqueline Anena; Abdoulaye Gueye; Marion Menozzi-Arnaud; Birgitte Giersing; Anna-Lea Kahn; Tiziana Scarna; Debra Kristensen
Journal:  Vaccine       Date:  2021-08-16       Impact factor: 3.641

4.  A method for estimating the impact of new vaccine technologies on vaccination coverage rates.

Authors:  Ben Davis; Michael Krautmann; Pascale R Leroueil
Journal:  PLoS One       Date:  2022-02-10       Impact factor: 3.240

5.  Innovations in vaccine delivery: increasing access, coverage, and equity and lessons learnt from measles and rubella elimination.

Authors:  James L Goodson; Paul A Rota
Journal:  Drug Deliv Transl Res       Date:  2022-02-24       Impact factor: 5.671

6.  Healthcare provider perspectives on delivering next generation rotavirus vaccines in five low-to-middle-income countries.

Authors:  Jessica Mooney; Jessica Price; Carolyn Bain; John Tanko Bawa; Nikki Gurley; Amresh Kumar; Guwani Liyanage; Rouden Esau Mkisi; Chris Odero; Karim Seck; Evan Simpson; William P Hausdorff
Journal:  PLoS One       Date:  2022-06-23       Impact factor: 3.752

7.  A Unified Hierarchical XGBoost model for classifying priorities for COVID-19 vaccination campaign.

Authors:  Luca Romeo; Emanuele Frontoni
Journal:  Pattern Recognit       Date:  2021-07-22       Impact factor: 7.740

8.  Evaluating the cost per child vaccinated with full versus fractional-dose inactivated poliovirus vaccine.

Authors:  Mercy Mvundura; Jui-Shan Hsu; Collrane Frivold; Debra Kristensen; Shanda Boyle; Darin Zehrung; Courtney Jarrahian
Journal:  Vaccine X       Date:  2019-07-15

9.  How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making.

Authors:  Siobhan Botwright; Anna-Lea Kahn; Raymond Hutubessy; Patrick Lydon; Joseph Biey; Abdoul Karim Sidibe; Ibrahima Diarra; Mardiati Nadjib; Auliya A Suwantika; Ery Setiawan; Rachel Archer; Debra Kristensen; Marion Menozzi-Arnaud; Ado Mpia Bwaka; Jason M Mwenda; Birgitte K Giersing
Journal:  Vaccine X       Date:  2020-10-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.